1. A vaccine composition for use in stimulating cellular immunity, comprising an antigen and at least one first promoter of stimulating cellular immunity, selected from the group consisting of a cyclooxygenase inhibitor, a prostaglandin receptor antagonist, a prostaglandin receptor agonist, a TSLP production inhibitor, an adenylate cyclase inhibitor, 3 om fatty acid, PPAR agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist a, a serotonin receptor agonist, a serotonin receptor antagonist, a vasopressin receptor antagonist, a vasopressin receptor agonist, a muscarinic receptor antagonist, a muscarinic receptor agonist, an adrenergic receptor antagonist, an adrenergic receptor agonist, an agonist agonist receptor agonist, an agonist agonist an opioid receptor agonist； an ADP receptor agonist； a leukotriene receptor antagonist； a leukotriene receptor agonist pterium, a melatonin receptor agonist, a somatostatin receptor agonist, a cannabinoid receptor agonist, a sphingosine 1-phosphate receptor agonist, a metabotropic glutamate receptor agonist, a phospholipase A2 inhibitor, a TGF-β production inhibitor, and a Th2.2 cytokine inhibitor. The vaccine composition according to claim 1, wherein the composition is intended for use in the treatment of cancer. The vaccine composition according to claim 1, wherein the composition is intended for use in the treatment of a viral disease. The vaccine composition according to claim 1, where the composition further comprises1. Вакцинная композиция, для применения в стимуляции клеточного иммунитета, содержащаяантиген ипо меньшей мере один первый промотор стимуляции клеточного иммунитета, выбранный из группы, состоящей из ингибитора циклооксигеназы, антагониста простагландинового рецептора, агониста простагландинового рецептора, ингибитора продукции TSLP, ингибитора аденилатциклазы, омега-3 жирной кислоты, агониста PPAR, антагониста дофаминового рецептора, агониста
